Results 281 to 290 of about 258,109 (297)

Psoriasis

Annales de Dermatologie et de Vénéréologie, 2006
openaire   +2 more sources

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Lancet, The, 2005
Kristian Reich, Christopher Em Griffiths
exaly  

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

New England Journal of Medicine, 2012
Claus Otto Carl Zachariae
exaly  

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

Lancet, The, 2015
herve bachelez, Peter C M Van De Kerkhof, Alexey Kubanov   +2 more
exaly  

The psoriasis drugs market

Nature Reviews Drug Discovery, 2015
exaly  

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

Lancet, The, 2006
Stephen K Tyring, David Cella
exaly  

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Lancet, The, 2008
Ka Papp, Kristian Reich
exaly  

Psoriasis

Medical Clinics of North America, 1982
openaire   +2 more sources

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

New England Journal of Medicine, 2011
Anne Puel, Celine V Cluzeau, Maya Chrabieh   +2 more
exaly  

Etanercept as Monotherapy in Patients with Psoriasis

New England Journal of Medicine, 2003
Alice B Gottlieb
exaly